What is Uterine Leiomyosarcoma

Uterine Leiomyosarcoma is a rare and aggressive form of cancer that originates in the smooth muscle cells of the uterus. Leiomyosarcoma accounts for only a small percentage of all uterine cancers, with most cases occurring in women over the age of 40. The exact cause of this cancer is unknown, but certain risk factors such as prior radiation therapy, genetic predisposition, and hormone replacement therapy may increase the likelihood of developing uterine leiomyosarcoma.

Common symptoms include abnormal vaginal bleeding, pelvic pain, and a palpable mass in the pelvic area. However, these symptoms are not specific to leiomyosarcoma and can be caused by other conditions as well. Diagnosis typically involves a combination of imaging tests, such as ultrasound and MRI, and a biopsy to confirm the presence of cancerous cells.

Treatment options for uterine leiomyosarcoma depend on the stage and extent of the cancer. Surgery, such as a hysterectomy, is often the primary treatment, aiming to remove the tumor and surrounding tissues. Radiation therapy and chemotherapy may be used before or after surgery to target any remaining cancer cells and reduce the risk of recurrence.

Prognosis for uterine leiomyosarcoma varies depending on the stage of the cancer at diagnosis and the individual's overall health. Early detection and prompt treatment can improve the chances of successful outcomes. Regular follow-up appointments and monitoring are crucial to detect any potential recurrence or metastasis.